These data combined with a safety profile that was consistent between participants with active SPMS and the overall EXPAND population (and consistent with that of S1P modulation) support the value of siponimod for the treatment of patients with SPMS. Here, MBTPS1 is linked to secondary progressive multiple sclerosis.